Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06698016
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc. (Site 0001), Overland Park, Kansas, United States
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 172
- Registration Number
- NCT05995249
- Locations
- 🇺🇸
Celerion - Tempe, AZ Site, Tempe, Arizona, United States
An Open-label DDI Study of Omaveloxolone in Healthy Subjects
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT05909644
- Locations
- 🇺🇸
Celerion, Inc., Tempe, Arizona, United States
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05330273
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Reverse Triple Negative Immune Resistant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05076682
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT05067439
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04680091
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, Shanghai, China
Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- University of Southern Denmark
- Target Recruit Count
- 10
- Registration Number
- NCT04504045
- Locations
- 🇩🇰
University of Southern Denmark, Odense, Region Of Southern Denmark, Denmark
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04459598
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04390334
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.